Steven Lee Kuklish

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2007-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven Lee Kuklish. Retrieved from https://idiyas.com/inventor/steven-lee-kuklish

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 40.0

CIPO Patents = 4

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 21(Granted Patents)

Company Filing History:

10 out of 4,514

Eli Lilly and Company

patents

Years Active: 2007-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11542249 - BTK inhibitor compounds (2023-01-03),

2. 9969714 - Carboxylic acid compounds useful for inhibiting microsomal prostaglandin E2 synthase-1 (2018-05-15),

3. 9962375 - [object Object] (2018-05-08),

4. 9776964 - Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators (2017-10-03),

5. 8642768 - Dimethyl-benzoic acid compounds (2014-02-04),

6. 8252831 - Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis (2012-08-28),

7. 7960419 - Substituted carboxamides (2011-06-14),

8. 7314879 - Melanocortin receptor agonists (2008-01-01),

9. 7169777 - Melanocortin receptor agonists (2007-01-30),

10. 7157463 - Substituted piperidines/piperazines as melanocortin receptor agonists (2007-01-02),

Title: Innovations and Contributions of Steven Lee Kuklish

Introduction

Steven Lee Kuklish is a prominent inventor based in Fishers, Indiana, known for his significant contributions to the field of pharmaceuticals. With a total of 10 patents to his name, Kuklish has made remarkable advancements in the development of therapeutic compounds.

Latest Patents

Among his latest innovations are BTK inhibitor compounds, which are designed to provide effective treatment options for various medical conditions. Additionally, he has developed carboxylic acid compounds that are useful for inhibiting microsomal prostaglandin E2 synthase-1. This invention includes compounds of a specific formula, along with methods for preparing these compounds and their applications in treating pain and inflammation.

Career Highlights

Kuklish is currently employed at Eli Lilly and Company, a leading pharmaceutical firm where he continues to push the boundaries of medical research and innovation. His work has been instrumental in advancing the understanding and treatment of complex health issues.

Collaborations

He collaborates with talented professionals in his field, including Matthew Joseph Fisher and Ryan Thomas Backer, who contribute to the innovative environment at Eli Lilly and Company.

Conclusion

Steven Lee Kuklish exemplifies the spirit of innovation in the pharmaceutical industry through his extensive patent portfolio and collaborative efforts. His work continues to impact the field positively, paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.